亚太药业(002370) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥123,584,310.47, representing an increase of 80.88% compared to ¥68,322,640.18 in the same period last year[4] - The net loss attributable to shareholders was ¥2,618,854.09, a 90.93% improvement from a loss of ¥28,871,344.89 in the previous year[4] - The net cash flow from operating activities improved by 73.72%, amounting to -¥2,493,862.07 compared to -¥9,488,898.62 in Q1 2022[10] - The company reported a significant increase in fair value gains of 156.76%, totaling ¥3,391,937.73, compared to a loss of -¥5,975,757.73 in the same period last year[8] - The weighted average return on equity improved to -0.87% from -6.89% year-on-year, reflecting a positive trend in financial performance[4] - The company reported a net loss of CNY 3,000,000 for Q1 2023, compared to a net loss of CNY 22,000,000 in the same period last year, indicating an improvement in financial performance[18] - The total comprehensive income for the first quarter was -2,618,854.09 CNY, compared to -28,871,344.89 CNY in the same period last year[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,491,227,644.74, a decrease of 2.13% from ¥1,523,620,705.13 at the end of the previous year[4] - The total assets as of the end of Q1 2023 were CNY 1,491,227,644.74, down from CNY 1,523,620,705.13 at the beginning of the year, a decrease of approximately 2.1%[16] - The total liabilities decreased to CNY 1,192,626,158.72 from CNY 1,222,400,365.02, reflecting a reduction of about 2.4%[16] Revenue and Expenses - The total operating revenue for Q1 2023 was CNY 123,584,310.47, an increase from CNY 68,322,640.18 in the same period last year, representing an increase of approximately 81.1%[18] - The total operating costs for Q1 2023 were CNY 126,382,479.22, up from CNY 90,768,431.38 in the previous year, indicating a rise of about 39.2%[18] - The gross profit margin for Q1 2023 was approximately -2.3%, compared to a gross profit margin of about 39.0% in the same period last year, reflecting a significant decline[18] - The total operating expenses increased to 69,756,339.18 CNY from 54,745,897.69 CNY, reflecting a rise of about 27.4%[22] - Research and development expenses rose to 4,608,303.89 CNY, compared to 3,772,402.86 CNY in the previous year, marking an increase of approximately 22.0%[20] Cash Flow and Equivalents - The company's cash and cash equivalents at the end of Q1 2023 were CNY 739,004,798.75, down from CNY 757,616,775.10 at the beginning of the year, a decrease of about 2.4%[14] - The cash and cash equivalents at the end of the period were 703,824,887.55 CNY, down from 778,696,857.36 CNY at the end of the previous year[22] - The net cash flow from investing activities improved by 43.31%, amounting to -¥1,136,941.50 compared to -¥2,005,559.40 in the previous year[10] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 72,891, with the largest shareholder holding 14.38% of the shares[11] - The basic and diluted earnings per share were both -0.0049 CNY, compared to -0.0538 CNY in the same quarter last year[20] Litigation - The company is currently involved in ongoing litigation related to securities false statements, with a total claim amount of CNY 8,556,600 from 238 investors, of which 145 have withdrawn their claims[13] Other Information - The company did not report any significant new product launches or technological advancements during this quarter[23]